Structural basis of drug resistance in the Malaria parasite

Description

Over half of the people on the planet are at risk from infection with the parasites that cause Malaria. In 2016, there were 216 million cases of the disease globally, resulting in 445 000 deaths. The best treatment for Malaria is currently via the combination of the drugs Artemisin and Piperaquine, but emerging resistance to both of these front-line antimalarial drugs means there is an urgent need for new treatment options and a better understanding of resistance mechanisms. This project will seek to understand the structural, biochemical and biophysical basis of antimalarial resistance, aiding the development of a new class of therapeutics against the parasite.

Updated:  27 May 2019/Responsible Officer:  Director RSB/Page Contact:  Webmaster RSB